SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 3.21 |
| Enterprise Value ($M) | -5.39 |
| Book Value ($M) | 7.04 |
| Book Value / Share | 4.71 |
| Price / Book | 0.46 |
| NCAV ($M) | 6.76 |
| NCAV / Share | 4.53 |
| Price / NCAV | 0.48 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.44 |
| Return on Assets (ROA) | -0.43 |
| Return on Equity (ROE) | -1.53 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.62 |
| Current Ratio | 1.66 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 17.24 |
| Assets | 17.52 |
| Liabilities | 10.48 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 10.25 |
| Operating Income | -5.20 |
| Net Income | -5.35 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -5.46 |
| Cash from Investing | 0.00 |
| Cash from Financing | 14.32 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Altium Capital Management LP | 4.99 | -81.39 | |
| 13G/A | Lytton Laurence W | 9.99 | -91.30 | |
| 13D/A | Nantahala Capital Management, LLC | 15.99 | 200.68 | |
| 13G/A | Hirschman Orin | 0.00 | -100.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K/A | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 2,916 | 7,659 | 38.07 | |
| 6,030 | 7,930 | 76.04 | |
| 428 | 5,830 | 7.34 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| EQ – Equillium, Inc. | ERNA – Ernexa Therapeutics Inc. |
| ESLA – Estrella Immunopharma, Inc. | EYEN – Eyenovia, Inc. |
| FBIO – Fortress Biotech, Inc. |
Financial data and stock pages provided by
Fintel.io